About Us Company News Cyagen and Biointron Forge Strategic Alliance, Opening a New Chapter in Antibody Drug Development

Cyagen and Biointron Forge Strategic Alliance, Opening a New Chapter in Antibody Drug Development

Biointron 2024-03-23 Read time: 6 mins

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development.

This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron's single B-cell antibody discovery expertise. Together, they will advance the development and commercialization of fully humanized antibody mice and discovery projects worldwide, empowering the development and clinical translation of antibody drugs.

Biointron CEO Zha Changchun and Cyagen CEO Han Lanqing.png
Left: Biointron CEO Zha Changchun | Right: Cyagen CEO Han Lanqing

At the signing ceremony, representatives from Biointron including CEO Zha Changchun, General Manager Cheng Qianwen, and Senior Vice President Dr. Shi Lei attended. From Cyagen, the moment was jointly witnessed by Chairman Han Lanqing, Board Secretary Zhong Wenjie, R&D Director Zhou Shun, Sales Director of the Greater China Region Yin Chunyang, and BD Manager of the Antibody Discovery Business Line Wang Zhiyu. 

Representatives from Biointron and Cyagen at the signing ceremony.png
Representatives from Biointron and Cyagen at the signing ceremony

Cyagen's independently developed HUGO-Ab™ fully humanized mice can produce fully humanized antibodies with high affinity and low immunogenicity in vivo. Its outstanding performance has shown good results in the antibody discovery process – receiving recognition from several multinational pharmaceutical companies, biopharmaceutical companies, and academic institutions. It provides an efficient R&D engine for the development of new therapeutic antibody drugs. 

Biointron's independently developed single B-cell antibody development platform leverages microdroplet microfluidics systems and efficient signal amplification technologies to achieve high-throughput identification of plasma cells secreting specific antibodies. It can complete the screening of 1~2x106 million plasma B cells within one day. The large number of positive cells obtained from screening, through Biointron's single-cell sequencing platform, allows for the acquisition of naturally paired antibody sequences within one week. This strategic partnership will accelerate the innovative pace of fully humanized antibody drug research and development. 

About Cyagen

Founded in 2006, Cyagen is an innovative CRO company that aims to accelerate new drug development with data, algorithms, and models. Relying on animal models and combining deep exploration in artificial intelligence, Cyagen leads the industry in the field of gene-edited animal models. From in-stock models, custom models, breeding, to phenotypic analysis, it fully and intelligently meets customers' needs for animal models in basic research and new drug development. Meanwhile, Cyagen continues to enrich its product line, establishing platforms such as preclinical pharmacology and pharmacodynamics CRO service platforms with a focus on cancer research, gene therapy CRO service platforms specializing in ophthalmic disease research, and antibody discovery platforms featuring fully humanized mice. Through these endeavors, Cyagen soars again in its strategic transformation. 

Cyagen currently has over 900 employees and more than 40,000 square meters of operation facilities. The company has wholly-owned subsidiaries in Guangzhou, Suzhou, and Gu'an in China, and offices in Chengdu, Beijing, Shanghai, Wuhan, and Changsha, as well as subsidiaries in Santa Clara, USA, and Tokyo, Japan. Cyagen has established extensive collaborations with scientists and enterprises in over 100 countries and regions worldwide. Its products and technologies have been directly applied in more than 10,000 academic papers, including those published in prestigious journals such as CNS (Cell, Nature, Science). Adhering to the corporate vision of creating unlimited possibilities for biotechnology, Cyagen is committed to collaborating with global medical research and development personnel to forge a bright future!

About Biointron

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, optimization and expression services for global biotech and pharmaceutical companies. 

Biointron holds a leading position in the antibody expression industry. From gene sequence to purified antibodies, it only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 1,500 biotech and pharma companies worldwide. 

We provide a one-stop solution for antibody discovery and optimization – including VHH antibody discovery, single B-cell antibody screening, hybridoma sequencing, antibody humanization, antibody affinity maturation, and more. Additionally, Biointron holds global sublicensing rights for ECACC's CHO-K1. Our CHOK1BN cell line, which is derived from CHOK1, has been filed in the DMF system with the US FDA. By choosing the CHOK1BN cell line, several partners’ projects have entered the multicenter international clinical trials successfully. For more information, please visit our official website www.biointron.com  or contact info@biointron.com

Subscribe to our Company News

Recent Company News

Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.

Mar 15, 2024
Company News

Celebrate International Women's Day with Biointron's female workforce!

Mar 15, 2024
Company News

Biointron is excited to announce our newly launched CHOK1-Fut8KO expression platform for afucosylated antibodies.

Aug 10, 2023
Company News

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.